A Nationwide Danish Comparative Effectiveness Study of GLP‐1 RA, SGLT2i and DPP‐4i Treatment on Risk of Stroke, Myocardial Infarction and Mortality in Type 2 Diabetes

Cardiovascular outcome trials have demonstrated that glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of major adverse cardiovascular events, whereas dipeptidyl peptidase‐4 inhibitors (DPP‐4i) have not shown cardiovascular benefits. We aimed to compare the effectiveness in routine clinical settings of incident use of either GLP‐1 RA, SGLT2i or DPP‐4i among type 2 diabetes on the stroke risk and as secondary outcomes myocardial infarction and all‐cause mortality.